Nasdaq:US$31.55 (-1.35) | HKEX:HK$54.80 (-0.35) | AIM:£5.08 (+0.01)
News & Press Releases
12345
6
7
found Documents: 311
London: Wednesday, 17 July 2013: Nutrition Science Partners, a 50/50 joint venture between Chi-Med and Nestlé Health Science, today announces that the first patient has begun treatment in the second global Phase III study of HMPL-004, NATRUL-4, for
Read More
Australia Phase I study to report in late 2013 London: Tuesday, 25 June 2013:  Chi-Med today announces that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, has initiated the Phase I clinical trial of Volitinib (HMPL-50
Read More
London: Wednesday, 24 April 2013: Nutrition Science Partners, a 50/50 joint venture between Chi-Med and Nestlé Health Science, today announces that the first patient has been enrolled and has begun treatment in the first global Phase III study of HM
Read More
London: Monday, 8 April 2013: Chi-Med today announces that data from the recently completed Phase I clinical trial of Fruquintinib (HMPL-013) and from preclinical studies of Volitinib (HMPL-504), two of the novel small molecule targeted anti-cancer d
Read More
London: Wednesday, 31 October 2012: Chi-Med announced that Hutchison MediPharma Limited (“HMP”), its majority owned R&D company, initiated the first-in-human Phase I clinical trial of Theliatinib (HMPL-309).  This is the fourth oncology comp
Read More
London: Wednesday, 22 February 2012: Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announces the initiation of the first-in-human Phase I clinical trial of Volitinib (HMPL-504) in Australia.  Volitinib
Read More
London: Wednesday, 21 December 2011: AstraZeneca and Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announce that they have entered into a global licensing, co-development, and commercialisation agreemen
Read More
London, Friday, 4 November 2011: Hutchison MediPharma Limited (“HMP”), the drug R&D company majority owned by Chi-Med, today announces the initiation of the first-in-human Phase I clinical trial of Epitinib (HMPL-813).  This is the third onc
Read More
London: Tuesday, 1 February 2011: Hutchison MediPharma Limited (“Hutchison MediPharma”), the drug R&D company majority owned by Chi-Med, today announces that it has started the first-in-human Phase I clinical trial of its anti-cancer drug can
Read More
London: Friday, 30 April 2010: Hutchison MediPharma Limited (“Hutchison MediPharma”), the wholly-owned drug R&D subsidiary of Chi-Med, today announces that it has initiated the first-in-human Phase I clinical trial of its anti-cancer drug can
Read More